Zevra Therapeutics (ZVRA) Short-term Investments (2015 - 2026)

Zevra Therapeutics (ZVRA) has 9 years of Short-term Investments data on file, last reported at $105.0 million in Q1 2026.

• Quarterly Short-term Investments rose 315.25% year-over-year to $105.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $105.0 million (up 315.25% YoY) and the FY2025 annual result came in at $128.6 million, up 260.13% from the prior year.
• Short-term Investments slipped to $105.0 million in Q1 2026, from $128.6 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $154.9 million in Q2 2025 to a low of $479000.0 in Q2 2023.
• A 5-year average of $56.3 million and a median of $30.3 million in 2024 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2023 — Short-term Investments surged 5032.64% — and 2024, when it jumped 44.65%.
• Tracing ZVRA's Short-term Investments over 5 years: stood at $481000.0 in 2022, then surged by 5032.64% to $24.7 million in 2023, then soared by 44.65% to $35.7 million in 2024, then surged by 260.13% to $128.6 million in 2025, then fell by 18.34% to $105.0 million in 2026.
• The last three Short-term Investments figures came in at $105.0 million (Q1 2026), $128.6 million (Q4 2025), and $145.1 million (Q3 2025), per Business Quant data.